此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Entrectinib (Rxdx-101) 在患有局部晚期或转移性实体瘤或原发性 CNS 肿瘤和/或没有令人满意的治疗方案的儿童和青少年中的研究 (STARTRK-NG)

2026年9月18日 更新者:Hoffmann-La Roche

Entrectinib (Rxdx-101) 在患有局部晚期或转移性实体瘤或原发性 CNS 肿瘤和/或没有令人满意的治疗方案的儿科患者中进行的 1/2 期、开放标签、剂量递增和扩展研究

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

研究概览

地位

主动,不招人

研究类型

介入性

注册 (实际的)

69

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国
        • Beijing Children's Hospital, Capital Medical University
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200082
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    • Ontario
      • Toronto、Ontario、加拿大、M5G 1X8
        • The Hospital for Sick Children
    • Baden-Wurttemberg
      • Heidelberg、Baden-Wurttemberg、德国、69120
        • Universitaetsklinikum Heidelberg
    • Lombardy
      • Milan、Lombardy、意大利、20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Lyon、法国、69373
        • Centre Leon Berard
      • Marseille、法国、13385
        • Hôpital de la Timone, Oncologie Pédiatrique
    • California
      • La Jolla、California、美国、92093-0706
        • University of California San Diego
      • San Francisco、California、美国、94158
        • UCSF Benioff Children's Hospital
    • Colorado
      • Aurora、Colorado、美国、80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Egleston Children's Hospital at Emory University Atlanta
    • Illinois
      • Chicago、Illinois、美国、60637
        • University of Chicago
    • Maryland
      • Baltimore、Maryland、美国、21205
        • Johns Hopkins University
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana Farber Cancer Institute
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University,St. Louis Children's Hospital
    • New York
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus、Ohio、美国、43205
        • Nationwide Children's Hospital
    • Oregon
      • Portland、Oregon、美国、97239
        • Oregon Health & Science Uni
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis、Tennessee、美国、38105
        • St. Jude Children'S Research Hospital
    • Texas
      • Houston、Texas、美国、77030
        • Texas Children's Cancer and Hematology Center
    • Utah
      • Salt Lake City、Utah、美国、84113
        • Primary Children's Hospital
      • London、英国、SW3 6JJ
        • Royal Marsden Hospital (Sutton)
      • Newcastle upon Tyne、英国、NE1 4LP
        • Royal Victoria Infirmary
      • Madrid、西班牙、28009
        • Hospital Infantil Universitario Nino Jesus
      • Hong Kong、香港、00000
        • Hong Kong Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1秒 至 18年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Disease status:

    • Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1

    • Phase 2 portion:

      • Part B: Participants must have measurable or evaluable disease, as defined by RANO
      • Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
      • Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
      • Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
  2. Tumor type:

    • Phase 1 portion:

      * Part A: Relapsed or refractory extracranial solid tumors

    • Phase 2 portion

      • Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
      • Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
  3. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse

  4. Archival tumor tissue from diagnosis or, preferably, at relapse

  5. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks

  6. Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive

  7. Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment

  8. Adequate organ and neurologic function

  9. Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.

  10. For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug

Exclusion Criteria:

  1. Receiving other experimental therapy
  2. Known congenital long QT syndrome
  3. History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
  4. Known active infections
  5. Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
  6. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  7. Prior treatment with approved or investigational TRK or ROS1 inhibitors
  8. Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
  9. Patients with NB with bone marrow space-only disease
  10. Incomplete recovery from acute effects of any surgery prior to treatment.
  11. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  12. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Extracranial solid tumors harboring NTRK1/2/3,

Arm closed for further enrollment

ROS1, ALK non-gene fusion molecular alterations

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

其他名称:
  • RXDX-101
有源比较器:CNS tumors harboring- NTRK1/2/3, ROS1, ALK

Arm closed for further enrollment

molecular alterations, including gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

其他名称:
  • RXDX-101
有源比较器:Neuroblastoma

Arm closed for further enrollment

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

其他名称:
  • RXDX-101
有源比较器:Non-neuroblastoma, extracranial solid tumors

Arm closed for further enrollment

harboring - NTRK1/2/3, ROS1, ALK gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

其他名称:
  • RXDX-101
有源比较器:Any participant unable to swallow capsules

Arm closed for further enrollment

Any participant who otherwise meet all other eligibility criteria

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

其他名称:
  • RXDX-101
有源比较器:Expansion: CNS tumors harboring NTRK1/2/3, ROS1

gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

其他名称:
  • RXDX-101
有源比较器:Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1

NTRK 1,2,3 and ROS1 fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

其他名称:
  • RXDX-101

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum Tolerated Dose (MTD)
大体时间:Approximately 6 months

Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
大体时间:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
大体时间:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
大体时间:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
大体时间:Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Cohort B: Objective Response Rate (ORR)
大体时间:Approximately 6 months

Assessed by RANO per the BICR

Approximately 6 months
Cohort D: ORR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR

Approximately 6 months

次要结果测量

结果测量
措施说明
大体时间
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
大体时间:Approximately 24 months

AE, ECG and Labs assessed by NCI CTCAE v4.03

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F1 Formulation
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using minitablets/F15
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F1 Formulation
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation given intact
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using minitablets/F15
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F1 Formulation
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation given intact
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation administered via feeding tube
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using minitablets/F15
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F1 Formulation
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using minitablets/F15
大体时间:Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Cohort A, D, or E: Clinical Benefit Rate (CBR)
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: CBR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: CBR
大体时间:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Progression-free Survival (PFS)
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: PFS
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: PFS
大体时间:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Overall Survival (OS)
大体时间:Approximately 6 months

Assessed by RECIST v1.1

Approximately 6 months
Cohort B or E: OS
大体时间:Approximately 6 months

Assessed by RANO

Approximately 6 months
Cohort A, D, or E: ORR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: ORR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: ORR
大体时间:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Time to response (TTR)
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: TTR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: TTR
大体时间:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Duration of Response (DOR)
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: DOR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: DOR
大体时间:Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
大体时间:Approximately 6 months

Assessed by RANO per the investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
大体时间:Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
大体时间:Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trials、Hoffmann-La Roche

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年5月3日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2016年1月4日

首先提交符合 QC 标准的

2016年1月7日

首次发布 (估计的)

2016年1月8日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • RXDX-101-03
  • CO40778 (其他标识符:Hoffmann-La Roche)
  • 2023-505088-35-00 (克蒂斯)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅